InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease.
We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.
Company Details
- Employees
- 52
- Founded
- -
- Address
- 2 Tower Pl,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- intervenn.bio
- Keywords
- biotech, artificial intelligence, proteomics, glycoproteomics, epiproteomics, mass spectrometry, LC-MS.
- HQ
- South San Francisco, California
Intervenn Biosciences Questions
Intervenn Biosciences's website is intervenn.bio
Intervenn Biosciences's LinkedIn profile is https://www.linkedin.com/company/intervenn
Intervenn Biosciences has
52 employees.
View email and phone details for 52
employees at Intervenn Biosciences.
Intervenn Biosciences's industry is
Biotechnology Research
Intervenn Biosciences's top competitors are
Alida Biosciences,
Arcadia Life Sciences,
Seer,
Alamar Biosciences, Inc.,
Netopia Ai,
Freenome,
Myome,
Vivum Ai,
Invitae,
Nmdp.
Intervenn Biosciences's categories are Biotechnology Research
Intervenn Biosciences's founding year is 2017
